Drug
Halofuginone clinical trials
Also written HT-100.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2001
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 1 |
| 2013 | 2 |
| 2015 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 2
Processa Pharmaceuticals (2) · National Cancer Institute (NCI) (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Akashi Therapeutics (1)
Related medicines
As reviewed, each with the page that says it.
- One of Angiogenesis Inhibitors source
Studies
Open first, then newest update. How each study uses halofuginone is read from its arms, and is right about nine times in ten.
Testing it · 5
- Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyTerminatedPhase 1/2Processa PharmaceuticalsNCT01847573Written as HT-100
- Open Label Extension Study of HT-100 in Patients With DMDTerminatedPhase 2Processa PharmaceuticalsNCT01978366Written as HT-100
- HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02TerminatedPhase 2Akashi TherapeuticsNCT02525302Written as HT-100
- Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's SarcomaCompletedPhase 2National Cancer Institute (NCI)NCT00064142Written as halofuginone hydrobromide
- Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid TumorsCompletedPhase 1European Organisation for Research and Treatment of Cancer - EORTCNCT00027677Written as halofuginone hydrobromide
Codes
What other systems call halofuginone · ClinicalTrials.gg INT002482
- MeSH (NLM) C010176halofuginoneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) L31MM1385EHALOFUGINONEConfirmed FDA, NLM, Wikidata
- UNII (FDA) H84E4Y7HC9HALOFUGINONE, (+)-Confirmed NLM, Wikidata
- UNII (FDA) NVY6A324PUHALOFUGINONE, (-)-Confirmed NLM, Wikidata
- Wikidata Q76118383HalofuginoneConfirmed FDA, NLM, Wikidata
- Wikidata Q4132745halofuginoneConfirmed NLM, Wikidata
- NCI Thesaurus C1120HalofuginoneOne source FDA
- DrugBank DB04866One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C010176 | halofuginone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | L31MM1385E | HALOFUGINONE | Confirmed FDA, NLM, Wikidata |
| UNII (FDA) | H84E4Y7HC9 | HALOFUGINONE, (+)- | Confirmed NLM, Wikidata |
| UNII (FDA) | NVY6A324PU | HALOFUGINONE, (-)- | Confirmed NLM, Wikidata |
| Wikidata | Q76118383 | Halofuginone | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4132745 | halofuginone | Confirmed NLM, Wikidata |
| NCI Thesaurus | C1120 | Halofuginone | One source FDA |
| DrugBank | DB04866 | — | One source Wikidata |
Also registered as halofuginone hydrobromide (UNII PTC2969MV1), halofuginone hydrobromide, (-)- (UNII Q86XE47UJ3), halofuginone hydrochloride (UNII 48NFA5XJV4) and halofuginone lactate (UNII 6ZO4HT041C).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.